Literature DB >> 7890819

Tower of London procedure: a standard method and developmental data.

R Krikorian1, J Bartok, N Gay.   

Abstract

The Tower of London procedure (TOL) is being utilized increasingly in clinical and experimental contexts, although there is considerable variation in how it is administered and scored. The procedure detailed here was developed using Shallice's original problems and, along with the Porteus Maze Test (PMT), was administered to 205 elementary school students and 74 young adults. TOL scores increased with age in a linear fashion, and the performance of the sixth, seventh, and eighth grade subjects were not statistically different from the young adults. The TOL was moderately correlated with the PMT suggesting that these procedures share a planning component. These data provide initial developmental standards, and the materials, administration, and scoring procedures documented here provide a standard method for utilization of this instrument.

Mesh:

Year:  1994        PMID: 7890819     DOI: 10.1080/01688639408402697

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  55 in total

1.  Which executive functioning deficits are associated with AD/HD, ODD/CD and comorbid AD/HD+ODD/CD?

Authors:  Jaap Oosterlaan; Anouk Scheres; Joseph A Sergeant
Journal:  J Abnorm Child Psychol       Date:  2005-02

2.  Tower of London performance in healthy adolescents: the development of planning skills and associations with self-reported inattention and impulsivity.

Authors:  Monica Luciana; Paul F Collins; Elizabeth A Olson; Ann M Schissel
Journal:  Dev Neuropsychol       Date:  2009       Impact factor: 2.253

3.  The Tower of London (ToL) in Italy: standardization of the ToL test in an Italian population.

Authors:  Maddalena Boccia; Dario Marin; Giovanni D'Antuono; Paola Ciurli; Chiara Incoccia; Gabriella Antonucci; Cecilia Guariglia; Laura Piccardi
Journal:  Neurol Sci       Date:  2017-04-21       Impact factor: 3.307

4.  Quality of life in persons after traumatic brain injury as self-perceived and as perceived by the caregivers.

Authors:  Rita Formisano; Eloise Longo; Eva Azicnuda; Daniela Silvestro; Mariagrazia D'Ippolito; Jean-Luc Truelle; Nicole von Steinbüchel; Klaus von Wild; Lindsay Wilson; Jessica Rigon; Carmen Barba; Antonio Forcina; Marco Giustini
Journal:  Neurol Sci       Date:  2016-11-08       Impact factor: 3.307

Review 5.  A meta-analysis of the effects of antidepressants on cognitive functioning in depressed and non-depressed samples.

Authors:  Catherine E Prado; Stephanie Watt; Simon F Crowe
Journal:  Neuropsychol Rev       Date:  2018-02-14       Impact factor: 7.444

6.  Development of a Psychiatric Disorder Linked to Cerebellar Lesions.

Authors:  Michela Lupo; Giusy Olivito; Libera Siciliano; Marcella Masciullo; Marco Bozzali; Marco Molinari; Maria Leggio
Journal:  Cerebellum       Date:  2018-08       Impact factor: 3.847

7.  Executive functioning in children with an Autism Spectrum Disorder: can we differentiate within the spectrum?

Authors:  Sylvie Verté; Hilde M Geurts; Herbert Roeyers; Jaap Oosterlaan; Joseph A Sergeant
Journal:  J Autism Dev Disord       Date:  2006-04

Review 8.  The role of radiotherapy in adult medulloblastoma: long-term single-institution experience and a review of the literature.

Authors:  M Balducci; S Chiesa; D Chieffo; S Manfrida; N Dinapoli; A Fiorentino; F Miccichè; V Frascino; C Anile; V Valentini; B De Bari
Journal:  J Neurooncol       Date:  2011-07-31       Impact factor: 4.130

9.  Structural cerebellar correlates of cognitive functions in spinocerebellar ataxia type 2.

Authors:  G Olivito; M Lupo; C Iacobacci; S Clausi; S Romano; M Masciullo; M Molinari; M Cercignani; M Bozzali; M Leggio
Journal:  J Neurol       Date:  2018-01-22       Impact factor: 4.849

Review 10.  Addictions Neuroclinical Assessment: A Neuroscience-Based Framework for Addictive Disorders.

Authors:  Laura E Kwako; Reza Momenan; Raye Z Litten; George F Koob; David Goldman
Journal:  Biol Psychiatry       Date:  2015-11-17       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.